Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for Preventing Keloid Recurrence
NCT03760250Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod in keloid, sponsored by University of Pennsylvania. Primary endpoint: Keloid Recurrence. Started Feb 2019; status: terminated.
02
Drugs
imiquimod
03
Conditions
keloid
Beyond the preview
Go deeper on NCT03760250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760250.